Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who previously progressed on erlotinib

Primo N Lara, Jeff Longmate, Philip Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp, David R Gandara

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who previously progressed on erlotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences